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Summary
High-fat diets cause peripheral leptin resistance, and dietary lipid composition affects sensitivity to leptin. We examined
the role of n-3 polyunsaturated fatty acid (PUFA) in peripheral leptin resistance. Dietary PUFAs (0.4% wt/wt) caused insen-
sitivity to peripherally but not intracerebroventricularly administered leptin. n-3 PUFA increased body weight, associated
with a significant reduction of leptin concentration in the cerebrospinal fluid. Dietary n-3 PUFA reduced transport of
endogenous or exogenously administered leptin into the brain, associated with increased expression of hypothalamic
occludin, but caused no change in expression of leptin receptors, proteins associated with leptin signaling or other tight
junction proteins. Continuous intracerebroventricular infusion of an antisense morpholino oligonucleotide targeted to oc-
cludin mRNA reversed n-3 PUFA-induced insensitivity to peripherally administered leptin. We conclude that n-3 PUFA
induces peripheral leptin resistance via an increase in the expression of hypothalamic occludin, reducing paracellular
transport of leptin into the brain.Introduction
The ob gene product leptin was discovered through study of
genetically obese (ob/ob) mice (Zhang et al., 1994). Leptin is a
16 kDa adipokine that regulates feeding behavior, repro-
duction, and immune function (Campfield et al., 1995; Halaas
et al., 1995; Cunningham et al., 1999; Okamoto et al., 2000).
Leptin, released from white adipose tissues, acts on the arcu-
ate nucleus of the hypothalamus to inhibit appetite, to stimu-
late sympathetic nerve activities, and to cause body weight
reduction in rodents (Campfield et al., 1995; Halaas et al.,
1995). Leptin is also known to stimulate secretion of LH and
FSH from the pituitary gland via hypothalamic GnRH release
and thereby activate the reproductive axis (Cunningham et al.,
1999). The central administration of leptin is known to suppress
specific functions of the lymphocytes via the activation of the
sympathetic nervous system (Okamoto et al., 2000). Leptin is
transported across the blood-brain barrier (BBB) and binds to
its specific receptor, which belongs to the class I cytokine re-
ceptor family. The long form of the leptin receptor (OB-Rb) is
activated by the formation of a homodimer. The intracellular
signal transduction of leptin is mediated predominantly through
the phosphorylation of the Janus kinase 2-signal transducer
and activator of transcription-3 (STAT-3) pathway (Tartaglia et
al., 1995; Vaisse et al., 1996). The SOCS-3 (suppressor of cy-
tokine signaling-3) pathway is a leptin-inducible inhibitor of lep-
tin signaling and has been suggested as a possible mediator
of leptin resistance in obesity (Bjorbaek et al., 1998).
In humans, the concentration of circulating leptin is well
correlated with body mass index (BMI), percentage of body fat,
and total body fat weight (Considine et al., 1996; Shimizu et
al., 1997) but is not related to body fat distribution (Shimizu etCELL METABOLISM : MAY 2005 · VOL. 1 · COPYRIGHT © 2005 ELSEVIEal., 1997). Restriction of dietary intake is also known to result
in a reduction of serum leptin concentration in humans (Shi-
mizu et al., 1997). Although obese patients exhibit high con-
centrations of circulating leptin, administration of endogenous
leptin clearly fails to inhibit appetite in these patients. This indi-
cates that these patients were resistant to leptin. A randomized
clinical trial confirmed that obese people are resistant to exog-
enously administered leptin and that high doses of leptin are
required to reduce body weight in obese patients (Heymsfield
et al. 1999). The ratio of cerebrospinal leptin concentration to
blood leptin concentration is clearly lower in obese people than
in lean subjects (Caro et al., 1996; Schwartz et al., 1996a), indi-
cating that the transport of leptin into the brain might be in-
terrupted in human obesity. These clinical data strongly indi-
cate that obese patients should exhibit peripheral leptin
resistance. However, the existence of peripheral leptin resis-
tance has yet to be confirmed, and the mechanisms involved
have yet to be elucidated. Moreover, high-fat diets are known
to cause peripheral leptin resistance (Van Heek et al., 1997; El-
Haschimi et al., 2000), and dietary lipid composition may affect
leptin sensitivity. Dietary intake of fish oil appears to influence
the regulation of appetite and obesity (Tisdale and Dhesis,
1990; Risica et al., 2000a; Risica et al., 2000b; Bjerregaard et
al., 2002). Our recent clinical data have demonstrated that se-
rum n-3 polyunsaturated fatty acid (PUFA) concentrations are
three times higher in obese subjects than in lean subjects (BMI,
20.5 ± 0.6 kg/m2) 1.36% ± 0.16% (n = 10), obese subjects
(BMI, 38.3 ± 1.3 kg/m2); 4.05% ± 0.26% (n = 19) (p < 0.01) (our
unpublished data). In addition, Westernization of the diet of In-
uit immigrants resulted in a reduction in the proportion of
obese people within this population (Bjerregaard et al., 2002),R INC. DOI 10.1016/j.cmet.2005.04.004 331
A R T I C L Eindicating that fish oil may play a role in the development of
human obesity.
Leptin is transported to the brain via the arcuate nucleus of
the hypothalamus (Banks, 2003; Schwartz et al., 1996b). While
FluoroGold does not penetrate the BBB, it is known to be read-
ily taken up by the arcuate nucleus, even when injected periph-
erally, suggesting that the arcuate nucleus BBB is poorly devel-
oped (Merchenthaler, 1991). Bioactive substances such as
leptin can move easily from the general circulation into the neu-
ronal space of the arcuate nucleus as compared to other re-
gions of the hypothalamus. Accumulating evidence suggests
that leptin resistance is due to impairment of the transport of
leptin from the blood to the brain (Baskin et al., 1998). Alter-
ations in the way that leptin is transported into the brain via
the BBB, along with hypothalamic leptin receptor abnormalities
and postreceptor signal transduction mechanisms, are pos-
sible contributory factors in the pathogenesis of peripheral lep-
tin resistance in obese patients. Fasting leads to a reduction in
the rate of leptin transport through the BBB and into the brain
(Kastin and Akerstrom, 2000), while α1-adrenergic stimulation
was shown to enhance the rate of leptin transport into the brain
(Banks, 2001). However, the critical mechanisms involved in
the regulation of leptin transport in the hypothalamus are not
yet fully understood, even in experimental models of obesity. It
was reported that New Zealand Obese (NZO) mice, an animal
model of obesity without any obvious genetic defects associ-
ated with the leptin receptor, exhibited peripheral leptin resis-
tance, as did rats fed upon a high-fat diet (Takahashi et al.,
2001). Similar results have also been demonstrated with hu-
man obesity. Both mouse and human models associated obe-
sity with reduced uptake of leptin by the brain, while neither of
the models exhibited significant reduction in Ob-R expression
in isolated cerebral microvessels (Hileman et al., 2002). We
have recently found that NZO mice exhibit a reduced ratio of
arachidonic acid (AA; n-6) to n-3 PUFA in the sera due to
changes associated with lipid metabolism-related enzyme
expression in adipose tissue (Takahashi et al., 2001). We
have also found a similar change in the ratio of AA to n-3
PUFAs in the sera of rats fed upon a high-fat diet (our unpub-
lished data).
The majority of the leptin in the arcuate nucleus of the hypo-
thalamus is derived from movement across the BBB and rarely
from blood-cerebrospinal fluid traveling via the choroid plexus
(Kurrimbux et al., 2004). It has been suggested that the recep-
tor-mediated transfer of leptin into the brain appears to occur
across the BBB via a saturable system (Banks et al., 1996).
However, the existence of a nonsaturable transport pathway
has also been proposed (Rubin and Staddon, 1999). In obesity,
the movement of leptin into the rat brain and cerebrospinal fluid
is not affected by saturation of the transport carriers. In gene-
ral, the transport of bioactive substances can be mediated
by both transcellular and paracellular mechanisms. Recent
studies have revealed that transport through the BBB can be
modulated to respond to environmental stimuli (Kastin and Ak-
erstrom, 2000; Banks, 2001). Changes of n-3 PUFA composi-
tion in brain endothelial cells forming the BBB may affect the
ability of leptin to move through the BBB. In the present study,
we first demonstrate that n-3 PUFAs cause peripheral leptin
resistance in rats resulting in obesity and then investigate a332mechanism of peripheral leptin resistance induced by an n-3
PUFA-rich diet.
Results
n-3 PUFA causes insensitivity to peripherally
administered leptin
Rats fed a high-fat (56%) diet for 14 days exhibited a signifi-
cant increase in serum levels of n-3 PUFA (high-fat-fed rats:
3.2% ± 0.4% [wt/wt], n = 8) when compared with rats fed a
low-fat diet (2.4% ± 0.2% [wt/wt], n = 8, p < 0.05). This trend
was not, however, observed with levels of n-6 PUFA. We exam-
ined the influence of fatty acid composition in a diet not con-
taining fish oil upon leptin activity in rats by measuring the ef-
fects of intraperitoneal (i.p.) injections of recombinant leptin
during the dark phase. Effects were monitored for a period of
3 hr following injection. Injections were made 7 days after rats
were first provided with the test diets. Body weight gain over
a 7 day period from the first provision of each of the test diet
days was significantly higher in rats fed diets containing EPA
or DHA than rats fed diets containing other fatty acids (fed non-
fish-oil-containing diet, 53.2 ± 1.8 g; stearic acid [18:0]-added
diet, 53.1 ± 1.2 g; oleic acid [18:1]-added diet, 52.2 ± 1.1 g;
linoleic acid [18:2]-added diet, 53.6 ± 1.4 g; docosahexaenoic
acid [DHA; 22:5]-added diet, 60.3 ± 2.6 g [p < 0.05]; eicosapen-
taenoic acid [EPA; 20:5]-added diet, 62.1 ± 1.5 g [p < 0.01]).
As shown in Figure 1, the addition of 0.4% (wt/wt) stearic acid,
oleic acid, and linoleic acid did not affect the anorexigenic ef-
fects of recombinant leptin on food intake over a period of 3
hr. In contrast, the addition of 0.4% (wt/wt) n-3 PUFA, EPA,
and DHA completely deleted the anorexigenic effects of re-
combinant leptin during this same time period. From these ob-
servations, it appears that dietary n-3 PUFAs are involved in
the development of insensitivity to peripherally administered
recombinant leptin, resulting in significant body weight gain
over a 7 day period.
In the next experiment, we determined how n-3 PUFAs de-
leted the anorexigenic effects of recombinant leptin by using
EPA. Serum concentration of n-3 PUFA in rats fed a diet con-
taining EPA was three times higher than that seen in rats fed a
control diet (non-n-3-PUFA-containing, 3.60% ± 0.91%; n-3-
PUFA-containing diet, 10.56% ± 1.61%, p < 0.05, n = 8 each
group). As with obese humans, rats fed a diet containing n-3
PUFA exhibited increased levels of n-3 PUFA in their blood.
Similar i.p. administration of recombinant leptin (0.5 g/g body
weight) significantly inhibited food intake for 1 hr in animals
fed a diet that did not contain fish oil (Figure 2Aa). Significant
suppression of feeding for a period of 3 hr was observed in
those animals receiving recombinant leptin (5.0 g/g body
weight) administered i.p. (Figure 2Ab). In contrast, i.p. admin-
istration of both 0.5 and 5.0 g/g body weight of recombinant
leptin did not show any significant reduction of food intake in
animals fed a diet containing 0.4% (wt/wt) n-3 PUFA (EPA) (Fig-
ures 2Ba and 2Bb). On the other hand, intracerebroventricular
administration of recombinant leptin inhibited food intake in a
dose-dependent manner in rats fed a diet containing n-3
PUFA, in a similar manner to control animals fed a diet not
containing PUFA (Figure 2C). These data confirmed that n-3
PUFA causes peripheral leptin resistance in rats. Evidence in
support of this is that the addition of n-3 PUFA completely de-
leted the anorexigenic effects of peripherally administered re-CELL METABOLISM : MAY 2005
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Effects of the addition of 0.4% (wt/wt) saturated
(stearic acid, 18:0), monounsaturated (oleic acid,
18:1), diunsaturated (linoleic acid, 18:2), or polyun-
saturated (EPA, 20:5; DHA, 22:5) fatty acids in diets
not containing fish oil on the anorexigenic effects of
i.p. administered recombinant leptin (5.0 g/gbw) in
rats. The addition of 0.4% (wt/wt) DHA or EPA sup-
pressed the anorexigenic effects of leptin for 3 hr
(n = 7–8/group). Data represent mean ± SE.combinant leptin. Moreover, intracerebroventricular administra-
tion of recombinant leptin also inhibited food intake in animals
fed a diet not containing fish oil and also a diet supplemented
with n-3 PUFA.
Leptin insensitivity by n-3 PUFA causes obesity
We next examined whether n-3 PUFA may result in increased
body weight due to peripheral leptin resistance and a conse-
quent increase in the proportion of body fat in treated rats (Ta-
ble 1). The rats fed a diet containing n-3 PUFA gained signifi-
cantly more body weight over a 2 week period (body weight
was measured on day 7 and day 14). Mesenteric white adipose
tissue weight was significantly higher in rats fed a diet contain-
ing n-3 PUFA for 3 days. At 14 days, subcutaneous, epidydi-
mal, and mesenteric white adipose tissue weight and inter-
scapular brown adipose tissue weight were found to be
significantly higher in animals fed a diet containing n-3 PUFA.
n-3 PUFA disturbs the transport of leptin into the brain
We examined changes in the hypothalamic transport of leptin
associated with the diet containing n-3 PUFA. Immunoreactive
leptin (IRL) concentrations in cerebrospinal fluid (CSF) were
significantly higher in rats fed a diet not containing fish oil than
in rats fed a diet containing n-3 PUFA without exogenous leptin
administration (Figure 2D), thereby indicating that the transport
of endogenous leptin may be disturbed by n-3 PUFA. Intraperi-
toneal administration of recombinant leptin significantly in-
creased CSF-IRL concentration in rats fed a diet not containing
fish oil but not in rats fed a diet containing n-3 PUFA. CSF
leptin concentration increased to 234 pg/ml in rats fed a diet
not containing fish oil compared to 83 pg/ml in rats fed a diet
containing n-3 PUFA. As shown in Table 1, n-3 PUFA increased
CSF-IRL concentrations over a 2 week period following initial
provision of the diet and was also associated with an increase
in serum IRL concentration at 14 days. In an effort to measure
the transport of exogenously administered leptin across the
BBB, we utilized human leptin and observed the transport of
this into the CSF by using an ELISA system that selectivity
measured human leptin. The concentration human leptin in ratCELL METABOLISM : MAY 2005CSF 60 min after the i.p. administration of human leptin was
significantly lower in rats fed a diet containing n-3 PUFA than
rats fed a diet not containing n-3 PUFA; this was in spite of
these groups of animals exhibiting a similar increase in serum
human leptin concentration (Figure 2E). The ratio of CSF to
serum human leptin was also significantly reduced in rats fed
a diet containing n-3 PUFA. These data indicated that the
transport of both endogenous and exogenous leptin appears
to be disturbed in animals fed diets containing n-3 PUFA.
Therefore, n-3 PUFA-rich diets may cause obesity due to the
development of peripheral leptin resistance.
Alterations in the expression of molecules associated
with the transport of leptin
How does n-3 PUFA manage to disturb the transport of leptin
through the BBB into the brain? It is possible that leptin might
be transported into the brain by two different pathways: trans-
cellular and paracellular. Possible candidate mechanisms in-
volved in peripheral leptin resistance include changes in leptin
binding capacity, leptin transport through the BBB, and postre-
ceptor signal transduction, which may modulate transcellular
leptin transport. Ob-Ra is capable of transporting intact leptin
across polarized epithelial cells in vitro (Hileman et al., 2000).
To investigate alterations in the transcellular transport of leptin
mediated by the leptin receptor, we evaluated changes in the
expression of the hypothalamic leptin receptor (Ob-Ra, short-
form; Ob-Rb, long-form) by feeding rats diets containing n-3
PUFA (Figure 3A). The expression of Ob-Ra and Ob-Rb was
unaffected by feeding rats a diet containing n-3 PUFA over a 7
day period. The concentration of the serum soluble leptin re-
ceptor (Ob-Re) may also be involved in the development of
peripheral leptin resistance (Huang et al., 2001; Zastrow et al.,
2003). However, there were no differences in serum concentra-
tions of Ob-Re when compared between rats fed a diet not
containing fish oil and those fed a diet supplemented with n-3
PUFA (Figure 3A). These data indicated that the binding capac-
ity of cell membrane-associated leptin and circulating leptin is
not changed by diets containing n-3 PUFA and that binding
capacities of the leptin receptor are not involved in n-3 PUFA-333
A R T I C L EFigure 2.
A−C) Changes in 0–1 hr and 1–3 hr food intake by i.p. ([A], 0.5 g/gbw; [B], 5.0 g/gbw body weight) and (C) intracerebroventricular (10–1000 ng/rat) recombinant
leptin administration in rats fed a diet not containing fish oil either without (Aa, Ba, Ca) or with 0.4% (wt/wt) n-3 PUFA (EPA) (Ab, Bb, Cb).
D) Changes in CSF immunoreactive leptin concentration as a result of an i.p. injection of 5.0 g/gbw recombinant leptin in rats fed a diet not containing fish oil either
without or with 0.4% (wt/wt) n-3 PUFA (EPA) (n = 8–16 in each group).
E) Changes in serum and CSF human immunoreactive leptin concentration and the ratio of CSF to serum human leptin concentration 60 min after an i.p. injection of
5.0 g/gbw of recombinant human leptin in rats fed a non-fish-oil-containing diet either without or with 0.4% (wt/wt) n-3 PUFA (EPA) (n = 6 in each group). Data
represent mean ± SE.induced peripheral leptin resistance. There were no obvious
differences in the expression of STAT-3, the phosphorylated
form of STAT-3 (p-STAT-3), and SOCS-3 prior to the administra-
tion of leptin when compared between diets with and without
n-3 PUFA. While leptin increased the phosphorylation of STAT-3
in rats fed diets not containing n-3 PUFA, rats fed EPA exhib-
ited no significant changes in the hypothalamic levels of SOCS-3,
STAT-3, and p-STAT-3 when measured 60 min after the i.p. ad-
ministration of leptin (Figure 3B).
On the other hand, bioactive substances are also trans-
ported into the neural spaces through the BBB by paracellular
mechanisms. There may be a possibility that the paracellular
transport of leptin may be modified by the presence of dietary
n-3 PUFA. The endothelial tight junctions consist of three inte-
gral membrane proteins: claudin, occludin, and junctional ad-
hesion molecule (JAM) (Morita et al., 1999; Furuse et al., 1993;
Bazzoni and Dejana, 2001; Maness et al., 2000). The develop-
ment of intercellular junctions seems to depend upon the ap-
pearance of high levels of the tight junction proteins claudin-5,
JAM-1, occludin, and ZO (Zonula Occludens)-1. We examined
the possibility that n-3 PUFA may modify expression of these334tight junction proteins in the hypothalamus (Figures 4A–4D).
The diet containing n-3 PUFA significantly increased hypothal-
amic occludin expression but did not affect expression of hy-
pothalamic claudin-5, JAM-1, or ZO-1. Occludin expression
was investigated in eight separate regions of the brain (Figure
4E). The diet containing n-3 PUFA resulted in increased expres-
sion of occludin in each region of the brain, indicating that the
effect of n-3 PUFA is widespread across the entire brain. The
increased expression of occludin was highest in the hypothala-
mus, a structure known to regulate feeding behavior. As shown
in Figure 4F, hypothalamic occludin expression had increased
by day 7 following the provision of the n-3 PUFA-containing
diet, and there was no difference in occludin expression when
compared between day 7 and day 14. The sensitivity to periph-
erally administered leptin was already reduced by day 3. At this
time point, hypothalamic occludin expression was increasing,
but circulating leptin levels remained unchanged (Figure 4G).
Furthermore, we measured the expression of occludin in
microvessels isolated from the hypothalamus. As shown in Fig-
ure 4H, n-3 PUFA clearly increased the expression of occludin
in the microvessels isolated from the hypothalamus. TheseCELL METABOLISM : MAY 2005
Leptin resistance by n-3 PUFATable 1. Chronological changes of body weight gain, adipose tissue weight, and leptin concentration by n-3 PUFA
Days/n-3 PUFA 3 days/(−) 3 days/(+) 7 days/(−) 7 days/(+) 14 days/(−) 14 days/(+)
BW (mg) 36.2 ± 2.5 43.0 ± 1.2 52.6 ± 7.1 67.4 ± 4.4a 104.3 ± 7.0 140.0 ± 7.5b
Sub (mg) 879.2 ± 53.6 924.5 ± 45.7 887.8 ± 108.9 1058.4 ± 59.3 1368.3 ± 97.4 1786.0 ± 132.6b
Epi (mg) 532.8 ± 41.0 584.0 ± 59.9 561.4 ± 32.2 719.6 ± 39.8b 1113.7 ± 50.9 1409.7 ± 62.5b
Mes (mg) 1234.4 ± 57.3 1580.3 ± 71.8b 1491.0 ± 87.8 1918.4 ± 118.2b 2132.0 ± 115.7 2661.6 ± 45.3b
Ret (mg) 458.4 ± 26.4 452.5 ± 18.5 479.8 ± 75.0 621.6 ± 49.3 987.6 ± 50.5 1307.6 ± 147.7
BAT (mg) 288.6 ± 36.0 306.5 ± 23.9 314.8 ± 25.3 377.8 ± 43.0 415.3 ± 40.3 543.6 ± 20.0b
S-Leptin (pg/ml) 2289.2 ± 309.9 2174.4 ± 203.7 2123.8 ± 261.7 2458.5 ± 342.2 2182.0 ± 361.2 2924.0 ± 295.2a
C-Leptin (pg/ml) 192.7 ± 50.3 171.0 ± 35.4 211.7 ± 39.9 146.0 ± 29.2b 209.6 ± 38.2 138.2 ± 31.5b
BW, body weight gain; Sub, subcutaneous white adipose tissue; Epi, epididymal white adipose tissue; Mes, mesenteric white adipose tissue; Ret, retroperitoneal
white adipose tissue; BAT, brown adipose tissue; S-Leptin, serum leptin concentration; C-Leptin, CSF leptin concentration.
ap < 0.05 versus rats fed non-n-3-PUFA-containing diet.
bp < 0.005 versus rats fed non-n-3-PUFA-containing diet.data indicated that an increase of hypothalamic occludin ex-
pression might be involved in n-3 PUFA-induced peripheral
leptin resistance.
Expression of hypothalamic occludin by n-3 PUFA
causes insensitivity to leptin
To investigate the possibility that overexpression of hypothala-
mic occludin is involved in n-3 PUFA-induced leptin resistance,
we used an antisense morpholino nucleotide against the oc-
cludin gene (40 g/day) and investigated its effect upon the
expression of hypothalamic occludin with or without n-3 PUFA
(Figure 5A). Chronic intracerebroventricular infusion of an anti-
sense morpholino oligonucleotide (40 g/day) designed against
occludin in rats fed a diet containing n-3 PUFA resulted in the
reduction of occludin expression to the level of animals fed
a diet not containing fish oil (Figure 5B, right panel). Chronic
intracelebroventricular infusion of a 5-missense morpholino oli-
gonuleotide failed to exhibit such a change in occudin expres-
sion. Body weight gain of rats administered with antisense that the overexpression of occludin by n-3 PUFA causes insen-
Figure 3.
A) Changes in the expression of hypothalamic Ob-Ra and Ob-Rb along with serum Ob-Re concentration in rats fed a diet not containing fish oil either without or with
0.4% (wt/wt) n-3 PUFA (EPA) (n = 8 in each group). No differences in leptin receptor expression were detected between these two groups.
B) Expression of hypothalamic SOCS-3, phosphorylated STAT3 (p-STAT3), and total STAT3 when measured 60 min after an i.p. injection of 5.0 g/gbw recombinant
leptin (n = 8 rats in each group). Data represent mean ± SE.CELL METABOLISM : MAY 2005morpholino oligonucleotides was significantly less than that
seen in rats administered with 5-missense morpholino oligonu-
leotide over a 7 day period (5-missense-treated rats; 39.2 ±
1.5 g, antisense-treated rats; 31.3 ± 2.1 g, p < 0.001). As
shown in the lower panel of Figure 5C, continuous infusion
(into the third ventricle) of antisense morpholino oligonucleo-
tides against occludin resulted in the reversal of n-3 PUFA-
induced leptin insensitivity. However, infusion of the 5-missense
morpholino oligonucleotide did not affect n-3 PUFA-induced
leptin insensitivity. Furthermore, chronic intracerebroventricular
infusion of an antisense morpholino oligonucleotide resulted in
reduced expression of hypothalamic occludin in rats fed diets
not containing n-3 PUFA (Figure 5B, left panel). Body weight
gain was not affected by the administration of the antisense
morpholino (5-missense-treated rats; 31.9 ± 2.1 g, antisense-
treated rats; 32.9 ± 2.3 g, not significant), and the sensitivity
to acute, peripheral leptin administration remained unchanged
(Figure 5C, upper panel). This observation strongly indicated335
A R T I C L EFigure 4.
A−D) Changes in the expression of hypothalamic (A) claudin-5, (B) JAM-1, (C) occludin, and (D) ZO-1 in rats fed a diet not containing fish oil either without or with
0.4% (wt/wt) n-3 PUFA (EPA) (n = 8 in each group). Expression of hypothalamic occludin was markedly elevated in rats fed a diet supplemented with n-3 PUFA.
E) Changes in occludin expression in eight separate regions of the brain in rats fed a diet supplemented with n-3 PUFA (n = 5 in each group).
F) Chronological change of occludin expression in the hypothalamus in rats fed a diet supplemented with n-3 PUFA (n = 5 in each group).
G) Changes in 0–1 hr and 1–3 hr food intake as a result of the i.p. administration of recombinant leptin without or with 0.4% (wt/wt) n-3 PUFA (EPA) at day 3 (n = 4–5
in each group).
H) Changes in the expression of occludin in microvessels isolated from the hypothalamus in rats fed a diet supplemented with n-3 PUFA (n = 6 in each group). Data
represent mean ± SE.sitivity to peripherally administered leptin. The observed in-
crease of occludin expression in the hypothalamus of rats fed
diets containing n-3 PUFA is expected to contribute to
changes in the transport of leptin through the BBB and into the
neural spaces.
Furthermore, we clarified the status of occludin expression
in other models of experimental obesity (Figure 6). Expression
of hypothalamic occludin was clearly increased in rats fed a
high-fat (56%) diet over a period of 14 days, during which se-
rum levels of n-3 PUFA were also significantly increased. On
the other hand, no such changes were found in genetic models
of obesity such as genetically obese (ob/ob) mice, genetically
diabetic (db/db) mice, and fatty Zucker rats.
Discussion
Composition of dietary nutrients may affect appetite. Leptin af-
fects preference to these nutrients. It has been established that336a high-fat diet can cause leptin resistance. However, at present
we know nothing about the possible relationship between dif-
ferent types of fatty acids and leptin resistance. NZO mice and
mice that have become obese as a result of a high-fat diet
have been reported to exhibit peripheral leptin resistance (Van
Heek et al., 1997; El-Haschimi et al., 2000; Burguera et al.,
2000). However, recent data demonstrated that central leptin
therapy fails to overcome the leptin resistance associated with
diet-induced obesity (Wilsey et al., 2003) and that obesity-
prone rats possess a normal blood brain barrier but defective
central leptin signaling pathways prior to the onset of obesity
(Levin et al., 2004). SOCS-3 is one of the possible candidates
involved in central leptin resistance, and an increase of SOCS-3
in the arcuate nucleus of the hypothalamus is known to be
related to region-specific leptin resistance (Munzberg et al.,
2004). Our present study first demonstrated that the addition
of n-3 PUFA caused peripheral leptin resistance in rats fed a
diet not containing fish oil. We also demonstrated that the ob-CELL METABOLISM : MAY 2005
Leptin resistance by n-3 PUFAFigure 5.
Changes in food intake in rats continuously infused intracerebroventricularly with 40 g/day of antisense or 5-missense morpholino oligonucleotides directed against
the rat occludin gene in animals fed a diet not containing fish oil either with or without 0.4% (wt/wt) n-3 PUFA (EPA). (A) Experimental protocol, (B) expression of
hypothalamic occluding, (C) chronological changes in 0–1 hr and 1–3 hr food intake following i.p. administration of recombinant leptin (0.5–5.0 g/gbw). Continuous
intracerebroventricular infusion of antisense morpholino oligonucleotide against occludin restored leptin’s anorexigenic effects in rats fed a diet rich in n-3 PUFA (n =
4–14 in each group). Data represent mean ± SE.served overexpression of hypothalamic occludin in rats fed
diets supplemented with n-3 PUFA is very likely to be involved
in the development of peripheral leptin resistance. The addition
of n-3 PUFA to diets may affect total caloric intake in the ani-
mals, thereby causing leptin resistance. However, an increase
in caloric intake caused by the addition of 0.4% n-3 PUFA is
trivial in this study (non-fish-oil-containing diet, 4 kcal/g, 0.4%
n-3 PUFA, 0.016 kcal/g − total calorie (n-3-PUFA-containing
diet) 4.016 kcal/g). It was noted that both groups of rats con-
sumed a very similar number of calories during the experiment,
and, therefore, the obesity observed in our model was due not
to an increase in total caloric intake but purely to the metabolic
effect of EPA.
The transport rates of intravenously administered leptin in
both leptin-receptor-deficient db/db mice and leptin-deficient
ob/ob mice do not differ from those of wild mice (Maness et
al., 2000). The CSF/plasma ratio of leptin was decreased by
10-fold in obese Koletsky rats, which have a mutation in theCELL METABOLISM : MAY 2005leptin receptor gene (Wu-Peng et al., 1997). Furthermore,
transport of leptin across the BBB of the Koletsky rat is known
not to be mediated by a product of the leptin receptor gene
(Banks et al., 2002). These previous observations strongly indi-
cate the existence of a leptin transport system that is indepen-
dent of the leptin receptor. In the present study, feeding rats a
diet rich in n-3 PUFA for 14 days resulted in increased concen-
trations of serum leptin concomitant with significant reduction
in the concentration of CSF leptin. As a result of this, there was
also a decrease in the CSF/serum ratio of leptin. A similar
change in ratio has been reported for obese humans. This find-
ing indicates that dietary n-3 PUFA is associated with de-
creased leptin uptake in the hypothalamus. However, the ex-
pression of both short and long forms of the leptin receptor in
the hypothalamus remained unchanged during the administra-
tion of a diet rich in n-3 PUFA. Therefore, it is possible that a
non-leptin-receptor-mediated transport system may play a role337
A R T I C L EFigure 6.
Changes in the expression of hypothalamic oc-
cludin in rats fed diets containing 10% fat and 56%
fat diet, ob/ob mice, db/db mice, Zucker fatty rats,
and lean littermates. The high-fat diet increased hy-
pothalamic occludin expression. In contrast, there
were no significant changes in the expression of hy-
pothalamic occludin when compared between lean
and obese mice and rats. Data represent mean ± SE.in the n-3-PUFA-induced disturbance of leptin transport into
the brain.
It has been reported that some proteins can be transported
by two different types of pathways: transcellular and paracellu-
lar (Broadwell et al., 1988; Quagliarello et al., 1991; Van Bree
et al., 1989). The present data indicate that a paracellular trans-
port system in brain endothelial cells may be important in
terms of leptin transport through the BBB into the brain. Two
membrane proteins, occludin and claudin, are mainly responsi-
ble for BBB function. Occludin consists of four loops through
the membrane and forms a homodimer with occludin from ad-
jacent cells. Polymers of occludin may form junctional fibrils
(Gumbiner, 1993), and it is known that occludin contributes to
increased cell-cell adhesion (Van Itallie and Anderson, 1997).
An increase in paracellular permeability to macromolecules is
associated with loss of total cellular occludin, indicating that
occludin plays a critical role in the tight junction permeability
barrier (Wong and Gumbiner, 1997). Furthermore, occludin is
known to regulate the paracellular transport of some proteins
in brain endothelial cells. The present study demonstrated a
significant increase of occludin expression in microvessels iso-
lated from the hypothalamus of rats fed a diet rich in n-3 PUFA.
Treatment of the human vascular endothelial cell line ECV304
with n-3 PUFA resulted in increased transendothelial cell resis-
tance, upregulated occludin expression, and reduced paracel-
lular permeability to large molecules (Jiang et al., 1998). EPA
exerted an upregulatory effect on occludin expression in this
cell line. Brain capillary endothelial cells cultured in EPA exhib-
ited an increase in trans-epithelial electrical resistance. Further-
more, expression levels of occludin messenger RNA increased
markedly after exposure to EPA, indicating that n-3 PUFA from
astrocytes may contribute to the formation of the BBB (Yama-
gata et al., 2003). Feeding rats a diet rich in n-3 PUFA resulted
in increased concentrations of circulating n-3 PUFA, which is
likely to contribute to increased expression of occludin in the
hypothalamus.
Dietary supplements of n-3 PUFA result in reduced expres-
sion of vascular endothelial growth factor (VEGF) in an animal
model of progressive malignancy (Tevar et al., 2002). VEGF in-
creases the permeability of a cultured brain microvessel endo-
thelial cell monolayer by influencing occludin expression (Wang
et al., 2001). Therefore, it is possible that n-3 PUFA may stimu-
late occludin expression via an increase in VEGF production in
the hypothalamus. However, the involvement of VEGF in the
observed increase of hypothalamic occludin expression in re-
sponse to n-3 PUFA can be ruled out, since hypothalamic
VEGF expression was not reduced in the present study by
feeding rats a diet rich in n-3 PUFA (data not shown).
Recently, occludin knockout mice have been reported to ex-
hibit delayed development and a significantly lower body338weight than wild mice (Saitou et al., 2000). These observations
are compatible with our own findings in that occludin is in-
volved in the regulation of body weight. It was not possible
for us to evaluate whether occludin knockout mice also exhibit
reduced food intake, reduced body fat, and increased CSF/
plasma ratio of leptin, since these factors have yet to be
studied in occludin knockout mice. It is known that the expres-
sion of truncated occludin increased both trans-epithelial
electrical resistance and flux of nontransported solutes with
molecular masses from 4 to 40 kDa but to a greater degree
than wild-type occludin (Balda et al., 1996). It is possible,
therefore, that leptin (16 kDa) may be easily transported
through the BBB into the brain in occludin knockout mice,
thereby delaying body development due to appetite reduction.
An increase of hypothalamic occludin expression by the addi-
tion of n-3 PUFA in the diet may induce leptin insensitivity by
reducing leptin transport to the feeding centers in the hypo-
thalamus.
It was demonstrated by clinical data that EPA administration
causes significant weight gain and an increase in dietary intake
in cachexic patients suffering from malignant tumors (Barber et
al., 2000; Wigmore et al., 2000). Westernization of diets also
reduced the proportion of obese people amongst Inuit immi-
grants (Risica et al., 2000a). These clinical observations sug-
gest that diet rich in n-3 PUFA causes increased body weight
in humans. In addition, our unpublished clinical data demon-
strated that n-3 PUFA concentrations were significantly higher
in the sera of massively obese Japanese subjects than lean
subjects, indicating that the n-3 PUFA component of brain en-
dothelial cell membrane may also be increased in these sub-
jects. These data raised the possibility that the observed
changes in hypothalamic tight junction-related peptide expres-
sion in response to supplementary dietary n-3 PUFA should
also be important in the regulation of appetite and metabolic
rates in obese people.
The present observations indicate that a diet rich in n-3
PUFA induces peripheral leptin insensitivity and that hypothala-
mic tight junction proteins are likely to be very important in the




Male Wistar rats weighing approximately 150 g were used throughout this
study. For studies involving a high-fat diet, the animals ate either a semisyn-
thetic low-fat (10% of Kcal as fat) or high-fat (56% of Kcal) diet (Shimizu et
al., 1994). Ob/ob mice, db/db mice, and their controls were used at an age
of 5 weeks. Zucker fa/fa rats and their lean littermates were used at an age
of 7weeks. All animals were housed individually in a temperature-controlled
room with a 12 hr light and 12 hr dark cycle (illumination from 6:00 to 18:00).
Food and water were available ad libitum. All experimental protocols wereCELL METABOLISM : MAY 2005
Leptin resistance by n-3 PUFAapproved by the Animal Use and Care Committee of the Gunma University
Graduate School of Medicine.
Blood chemistry
Serum n-3 PUFA concentration in human and rats was measured by gas
column chromatography. After transmethylation, fatty acid methyl esters
were extracted and quantified with a gas column chromatography system
(Hewlett-Packard Model HP6890, USA). The results are expressed as a per-
centage (weight/weight) and can be defined as the relative percentage of
each fatty acid concentration within a given serum lipid concentration.
Commercially available kits were used to measure immunoreactive leptin
concentrations in serum (Pharmacia, Linco Research, St. Charles, USA) and
CSF (Immuno-Biological Laboratories, Inc. Ltd., Fujioka, Gunma, Japan).
Feeding experiments
All animals were habituated to a powdered chow diet that did not contain
fish oil (Funabashi Farm, Chiba, Japan) with or without 0.4% wt/wt stearic
acid, oleic acid, linoleic acid (Sigma-Aldrich Chem. Co., St. Louis, MO,
USA), DHA (WAKO Pure Chemical Industries, Osaka, Japan), and EPA
(Mochida Pharmaceuticals, Co., Tokyo, Japan) for 7 days prior to the start
of each experiment.
For the acute experiments, recombinant leptin (0.5 or 5.0 g/g body
weight, R&D Systems, Minneapolis, MN, U.S.A.) dissolved in distilled water
or a vehicle solution was injected by i.p. or intracerebroventricular (ICV)
routes at 18:00 hr, and subsequent changes in the animals’ food consump-
tion were measured to the nearest 0.1 g. ICV infusion of recombinant leptin,
or vehicle, was performed through a 29-gauge injection cannula, which was
inserted through a 23-gauge guide cannula stereotaxically implanted into
the third ventricle of rats 7 days earlier (Uehara et al., 1998). Recombinant
leptin (5–500 ng/rat, dissolved in 5 l of distilled water) or a vehicle solution
was infused for 2–3 min through a polyethylene tube connected to a 25 l
microsyringe. Following the infusion, the injection cannula was maintained
in the guide cannula for at least 3 min to prevent backflow, after which
each animal was returned to its own cage. Food intake was then measured
chronologically for all rats in this study.
CSF collection
Rats were anesthetized by the administration of 40 mg/kg pentobarbital
(i.p.) by cisternal puncture with a 28-gauge needle. CSF was then collected
from anesthetized rats that did not receive leptin and those that were in-
jected with leptin (i.p.) 1 hr earlier (Seki et al., 1994). CSF was slowly col-
lected into the syringe, and the collection was immediately terminated when
blood appeared. On average, 70–80 l of CSF was obtained per rat. Centri-
fuged samples were frozen at −20°C until use.
Microvessel isolation
Cerebral microvessels were isolated from rat brain by the method described
previously (Nonaka et al., 2004). Two brain hypothalami were collected from
male Wister rats (n = 6) and homogenized gently with a Dounce tissue
grinder in ice-cold stock buffer (pH 7.4; 1% dextran in minimam essential
medium [GIBCO-BRL, Grand Island, NY, USA]) with 25 mM HEPES on ice.
The homogenized tissue was filtered through a nylon mesh net (308 m
followed by 108 m two times), mixed with an equal volume of 40% dextran
in cold stock buffer, and centrifuged at 5000 × g for 15 min at 4°C. The
pellet was then resuspended in stock buffer, filtered through a 25 m nylon
mesh membrane, washed from the surface of the membrane with stock
buffer four times, collected, and centrifuged at 5000 × g for 15 min at 4°C.
Isolated microvessels were then stored at −80°C until the assay.
Leptin transport assay
Rats were anesthetized by i.p. administration of 40 mg/kg pentobarbital.
Blood was sampled from the right jugular vein 60 min after the i.p. admin-
istration of human immunoreactive leptin and CSF collected by cisternal
puncture at the same time point. A commercially available human leptin
ELISA kit (Immuno-Biological Laboratories, Inc. Ltd., Fujioka, Gunma, Ja-
pan) was used to measure immunoreactive human leptin concentrations in
serum and CSF. In this assay kit, crossreactivity with rat leptin was less
than 0.1%.CELL METABOLISM : MAY 2005Western blot analyses
Proteins were extracted for immunoblot analysis. Dissected rat hypothalami
were lysed in ice-cold Tris-HCl buffer containing NP-40, phenylmethylsulfo-
nylfluoride (PMSF), leupeptin, pepstatin, and sodium vanadate. Following
protein determination using the method described by Lowry (Lowry et al.,
1951), 20 g of protein was separated using SDS-PAGE electrophoresis on
a 12.5% gel. Separated proteins were then transferred onto nitrocellulose
membranes. Membranes were first preblocked with nonfat milk at room
temperature for 1 hr and were then incubated with primary antibodies over-
night at 4°C. Primary antibodies against the three rat leptin receptor forms
(Ob-Ra, Ob-Rb, Ob-Re) as well as occludin, SOCS-3, phosphorylated
STAT-3, and STAT-3 were obtained from Santa Cruz Biotechnology Inc.
(Santa Cruz, CA, USA). Primary antibodies against rat claudin-5 and rat
ZO-1 were obtained from Zymed (South San Francisco, CA, USA). An anti-
body against rat JAM-1, the second antibody, and goat anti-rabbit IgG were
obtained from Jackson ImmunoResearch Laboratories, Inc. (West Balti-
more, PA, USA). Finally, membranes were washed in Tris-buffered saline
containing Tween 20 and positive antibody binding detected using
chemifluoresence ECL plus (Amersham Biosciences, UK).
Antisense morpholino oligonucleotide against occludin
The antisense and 5-missense morpholino oligonucleotides against rat oc-
cludin were obtained from Gene Tools, LLC (Philomath, OR, USA). The se-
quences of the antisense and 5-missense morpholino oligonucleotides
were CATGGCTGATGTCACTGGTCACCTG and CAAGGGTGATGTGACTG
GTGACGTGA, respectively. These oligos were continuously infused (40 g/
day) into the third ventricle using Alzet osmotic mini-infusion pumps (Cuper-
tino, CA, USA) via a cannula that was implanted 7 days prior to the start of
the infusion. The infusion period used for the oligonucleotide was deter-
mined in preliminary experiments (data not shown). Food intake in response
to leptin administration (5.0 g/g body weight) following the continuous
infusion of each morpholino oligonucleotide over a 7 day period was mea-
sured, as described earlier.
Data analysis
Results are expressed as mean ± SEM. Significant differences between
groups were evaluated using analysis of variance (ANOVA) followed by
Newman-Keuls test.
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